Ocumension Therapeutics announced that, OT-703 (ILUVIEN, fluocinolone intravitreal implant), an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema (DME) has recently obtained an approval from the Pharmacy and Poisons Board of Hong Kong for its registration as a pharmaceutical product in Hong Kong in accordance with the Pharmacy and Poisons Ordinance (Cap. 138 of the Laws of Hong Kong) (the Pharmacy and Poisons Ord finance). Upon the successful registration as a pharmaceutical product, OT-703 is allowed to be sold, offered for sale, distributed and possessed in Hong Kong for the purposes of the Pharmacy and PoisonsOrdinance.

OT-703, namely the 190 microgram fluocinolone acetonide intravitreal implant in applicator (0.19 mg), is an injectable, non- biodegradable fluocinOLone acetate intravit real implant and used for treatment of DME by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone ac Princetonide (FAc) in the eye, for up to 36 months. It has received the regulatory approval from the United States Food and Drug Administration (FDA) and marketed under the trade name "ILUVIEN". It is the only FDA-approved corticosteroid intraocular implant for the treatment of DME with a three-year sustained-release period.

In April 2021, the Company and Alimera Sciences Inc. (Alimera) entered into an exclusive license agreement, pursuant to which the Company obtained the exclusive licensed rights from Alimera in relation to the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.